Class II

Drug Recall: Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmac

Breckenridge Pharmaceutical, Inc. · November 24, 2025

Reason for Recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Product Description

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.

Distribution

Nationwide within the United States

States Affected

NATIONWIDE

Quantity Affected

7389 bottles

Source: FDA (openFDA Drug Enforcement)

Recall number: D-0216-2026

Status: ongoing

SafeCheck provides drug interaction information from FDA-approved product labeling (openFDA). This is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions.

Breckenridge Pharmaceutical, Inc. Drug Recall: Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmac | SafeCheck